Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line

The combination of ribociclib, fulvestrant, and buparlisib or alpelisib is being developed for the treatment of HR+ and HER2- locally recurrent or advanced metastatic breast cancer. Ribociclib is given by mouth (capsules). It acts by helping to slow the progression of cancer by inhibiting two certain types of proteins that play a role in ensuring that cancer cells do not grow uncontrollably. Buparlisib and alpelisib are other types of drugs that act by reducing tumour cell growth and survival. Both are also given by mouth. Fulvestrant is a drug that is given by injection and is already in use for the treatment of advanced breast cancer. If licensed, the combination of ribociclib, fulvestrant, and buparlisib or alpelisib will offer an additional treatment option for postmenopausal women with HR+, HER2-negative locally recurrent or advanced metastatic breast cancer.